卵巢癌组织中C-erbB-2和C-myc原癌基因扩增的研究

THE STUDY ON THE AMPLIFICATION OF C-erbB-2AND C-myc PROTOONCOGENE IN OVARIAN CARCINOMA

应用斑点杂交技术对３６例卵巢癌石蜡包埋组织进行了Ｃ－ｅｒｂＢ－２和Ｃ－ｍｙｃ原癌基因扩增的研究。结果表明，Ｃ－ｅｒｂＢ－２原癌基因扩增者１２例，扩增率为３３％，扩增集中于组织学Ⅲ级；Ｃ－ｍｙｃ原癌基因扩增者１０例，扩增率为２７．８％，扩增与组织学分级无关。Ｃ－ｅｒｂＢ－２扩增与ＤＮＡ倍体水平有关，与临床分期无关：Ｃ－ｍｙｃ扩增与倍体水平无关且多见于临床晚期。提示Ｃ－ｅｒｂＢ－２原癌基因扩增可用于判断卵巢癌的恶性程度，Ｃ－ｍｙｃ扩增有助于卵巢癌的临床分期。

ln order to assess the amplification of C-erbB-2 & C-myc proto-oncogene in ovarian carcinoma , Dot-blot hybridization technique was used . Among 36 case. , the rate of amplification of the two oncogenes was 33.3% and 27.8% respectively , the amplification of C-erbB-2 mainly clustered in histologic grade Ⅲ and there was no relationship between C- myc. amplifiction and histopathologic grade . The C-erbB-2 in 12 cases was all heteroploid and the C-myc amplification did not associate with DNA ploidy patterns. The amplification of C-erbB-2 did not correlate with clinical stage and C-myc amplification mainly occured in late clinical stage. This study shows that C-erbB-2 amplification can be used as an important parameter reflecting the malignacy of ovarian . carcinoma and C-myc amplification was conductive to judge clinical stage of the cancer,